LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel
December 29, 2021 04:00 ET | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid®-docetaxel is low and that the study demonstrated activity in both...
LIDDS tillkännager positiva topline resultat från den dos-eskalerande fas I studien av NanoZolid®-formulerad docetaxel
December 29, 2021 04:00 ET | LIDDS AB
UPPSALA, SVERIGE – LIDDS AB (publ) tillkännagav i dag att den systemiska exponeringen av docetaxel efter behandling av solida tumörer med NanoZolid®-formulerad docetaxel är låg och att studien visar...
Retrophin Logo.jpg
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
March 09, 2020 08:00 ET | Retrophin, Inc.
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
June 17, 2019 06:00 ET | VBI Vaccines, Inc.
Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 yearsSeroprotection rates four weeks post-3rd vaccination of...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
June 16, 2019 12:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...